{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:49:07Z","timestamp":1748468947942},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck KGaA, Darmstadt, Germany"},{"name":"Pfizer, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40271-018-0301-0","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T06:55:48Z","timestamp":1520319348000},"page":"439-449","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences"],"prefix":"10.1007","volume":"11","author":[{"given":"Howard L.","family":"Kaufman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Dias Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Guillemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9my","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Mahnke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murtuza","family":"Bharmal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,6]]},"reference":[{"issue":"Suppl 7","key":"301_CR1","doi-asserted-by":"publisher","first-page":"vii81","DOI":"10.1093\/annonc\/mdq366","volume":"21","author":"JC Becker","year":"2010","unstructured":"Becker JC. Merkel cell carcinoma. Ann Oncol. 2010;21(Suppl 7):vii81\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdq366 .","journal-title":"Ann Oncol."},{"issue":"4","key":"301_CR2","first-page":"290","volume":"97","author":"CW Oram","year":"2016","unstructured":"Oram CW, Bartus CL, Purcell SM. Merkel cell carcinoma: a review. Cutis. 2016;97(4):290\u20135.","journal-title":"Cutis"},{"issue":"1","key":"301_CR3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.virol.2012.09.029","volume":"435","author":"ME Spurgeon","year":"2013","unstructured":"Spurgeon ME, Lambert PF. Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential. Virology. 2013;435(1):118\u201330. https:\/\/doi.org\/10.1016\/j.virol.2012.09.029 .","journal-title":"Virology."},{"issue":"24","key":"301_CR4","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1158\/0008-5472.CAN-15-1877","volume":"75","author":"SQ Wong","year":"2015","unstructured":"Wong SQ, Waldeck K, Vergara IA, Schroder J, Madore J, Wilmott JS, et al. UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas. Cancer Res. 2015;75(24):5228\u201334. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1877 .","journal-title":"Cancer Res."},{"key":"301_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13828","author":"PK Goon","year":"2016","unstructured":"Goon PK, Greenberg DC, Igali L, Levell NJ. Merkel cell carcinoma: rising incidence in the east of England. J Eur Acad Dermatol Venereol. 2016. https:\/\/doi.org\/10.1111\/jdv.13828 .","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"301_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13698","author":"O Zaar","year":"2016","unstructured":"Zaar O, Gillstedt M, Lindelof B, Wennberg-Larko AM, Paoli J. Merkel cell carcinoma incidence is increasing in Sweden. J Eur Acad Dermatol Venereol. 2016. https:\/\/doi.org\/10.1111\/jdv.13698 .","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"8","key":"301_CR7","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/000313481508100819","volume":"81","author":"TL Fitzgerald","year":"2015","unstructured":"Fitzgerald TL, Dennis S, Kachare SD, Vohra NA, Wong JH, Zervos EE. Dramatic increase in the incidence and mortality from Merkel cell carcinoma in the United States. Am Surgeon. 2015;81(8):802\u20136.","journal-title":"Am Surgeon."},{"key":"301_CR8","unstructured":"National Comprehensive Cancer Network website. NCCN clinical practice guidelines in oncology, Merkel cell carcinoma, version 1. 2017. http:\/\/www.nccn.org . Accessed 12 Oct 2017."},{"issue":"1","key":"301_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jss.2012.03.067","volume":"177","author":"MC Soult","year":"2012","unstructured":"Soult MC, Feliberti EC, Silverberg ML, Perry RR. Merkel cell carcinoma: high recurrence rate despite aggressive treatment. J Surg Res. 2012;177(1):75\u201380. https:\/\/doi.org\/10.1016\/j.jss.2012.03.067 .","journal-title":"J Surg Res."},{"issue":"16","key":"301_CR10","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/j.ejca.2015.06.131","volume":"51","author":"C Lebbe","year":"2015","unstructured":"Lebbe C, Becker JC, Grob JJ, Malvehy J, Del Marmol V, Pehamberger H, et al. Diagnosis and treatment of Merkel cell carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(16):2396\u2013403. https:\/\/doi.org\/10.1016\/j.ejca.2015.06.131 .","journal-title":"Eur J Cancer."},{"key":"301_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30364-3","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D\u2019Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016. https:\/\/doi.org\/10.1016\/S1470-2045(16)30364-3 .","journal-title":"Lancet Oncol."},{"issue":"26","key":"301_CR12","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1603702 .","journal-title":"N Engl J Med"},{"issue":"3","key":"301_CR13","first-page":"161","volume":"28","author":"A Grant","year":"2011","unstructured":"Grant A. Fear, confusion and participation: Incapacity Benefit claimants and (compulsory) Work Focused Interviews. Res Policy Plan. 2011;28(3):161\u201371.","journal-title":"Res Policy Plan"},{"issue":"1","key":"301_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5172\/conu.12.1.58","volume":"12","author":"L Sweet","year":"2002","unstructured":"Sweet L. Telephone interviewing: is it compatible with interpretive phenomenological research? Contemp Nurse. 2002;12(1):58\u201363.","journal-title":"Contemp Nurse."},{"key":"301_CR15","unstructured":"Friese S. ATLAS.ti 7 user guide and reference. Berlin, Germany. 2014 http:\/\/atlasti.com\/wp-content\/uploads\/2014\/05\/atlasti_v7_manual_201312.pdf?q=\/uploads\/media\/atlasti_v7_manual_201312.pdf . Accessed 5 Jan 2016."},{"key":"301_CR16","doi-asserted-by":"publisher","DOI":"10.4135\/9780857025012","volume-title":"Using software in qualitative research: a step-by-step guide","author":"A Lewins","year":"2007","unstructured":"Lewins A, Silver C. Using software in qualitative research: a step-by-step guide. London: SAGE Publications; 2007."},{"key":"301_CR17","volume-title":"Transforming qualitative information: thematic analysis and code development","author":"R Boyatzis","year":"1998","unstructured":"Boyatzis R. Transforming qualitative information: thematic analysis and code development. Thousand Oaks: Sage; 1998."},{"key":"301_CR18","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf . Accessed 1 Mar 2018."},{"issue":"3","key":"301_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.pec.2010.12.021","volume":"82","author":"N Britten","year":"2011","unstructured":"Britten N. Qualitative research on health communication: what can it contribute? Patient Educ Couns. 2011;82(3):384\u20138. https:\/\/doi.org\/10.1016\/j.pec.2010.12.021 .","journal-title":"Patient Educ Couns."},{"key":"301_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-002889","author":"A O\u2019Cathain","year":"2013","unstructured":"O\u2019Cathain A, Thomas KJ, Drabble SJ, Rudolph A, Hewison J. What can qualitative research do for randomised controlled trials? A systematic mapping review. BMJ Open. 2013. https:\/\/doi.org\/10.1136\/bmjopen-2013-002889 .","journal-title":"BMJ Open."},{"issue":"7","key":"301_CR21","doi-asserted-by":"publisher","first-page":"e005566","DOI":"10.1136\/bmjopen-2014-005566","volume":"4","author":"FM Walter","year":"2014","unstructured":"Walter FM, Birt L, Cavers D, Scott S, Emery J, Burrows N, et al. \u2018This isn\u2019t what mine looked like\u2019: a qualitative study of symptom appraisal and help seeking in people recently diagnosed with melanoma. BMJ Open. 2014;4(7):e005566. https:\/\/doi.org\/10.1136\/bmjopen-2014-005566 .","journal-title":"BMJ Open."},{"key":"301_CR22","doi-asserted-by":"crossref","unstructured":"Iyer J, Blom A, Doumani R, Lewis C, Anderson A, Ma C et al., editors. Response rate and durability of chemotherapy for metastatic Merkel cell carcinoma among 62 patients. In: American Society of Clinical Oncology (ASCO) 50th annual meeting; 2014 30\/05\/2014 to 03\/06\/2014; Chicago, IL.","DOI":"10.1200\/jco.2014.32.15_suppl.9091"},{"issue":"4","key":"301_CR23","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.clinthera.2016.03.010","volume":"38","author":"Y Hao","year":"2016","unstructured":"Hao Y, Krohe M, Yaworsky A, Shields AL, Mazar I, Foley C, et al. Clinical trial patient-reported outcomes data: going beyond the label in oncology. Clin Ther. 2016;38(4):811\u201320. https:\/\/doi.org\/10.1016\/j.clinthera.2016.03.010 .","journal-title":"Clin Ther."},{"issue":"10","key":"301_CR24","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1093\/annonc\/mdq721","volume":"22","author":"T Luckett","year":"2011","unstructured":"Luckett T, King MT, Butow PN, Oguchi M, Rankin N, Price MA, et al. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol. 2011;22(10):2179\u201390. https:\/\/doi.org\/10.1093\/annonc\/mdq721 .","journal-title":"Ann Oncol"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40271-018-0301-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-018-0301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-018-0301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:36:07Z","timestamp":1603931767000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40271-018-0301-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,6]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["301"],"URL":"https:\/\/doi.org\/10.1007\/s40271-018-0301-0","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,6]]},"assertion":[{"value":"6 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by and is part of an alliance between Merck KGaA and Pfizer, Inc, NY, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MB is an employee of Merck KGaA, Darmstadt, Germany. CDB and IG, employees of Mapi at the time the study was performed, and JL, an employee of Mapi, were paid consultants to Merck KGaA, Darmstadt, Germany. HK has served on advisory boards for Amgen, Celldex, Compass Therapeutics, EMD Serono, Merck, Prometheus, Sanofi and Turnstone Biologics. He has also served on a speakers\u2019 bureau for Merck, but all honoraria were given to Rutgers University. LM is an employee of EMD Serono, Boston, USA. The authors did not receive payment for authorship.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All participants provided written informed consent prior to any study-related procedures, including patient interviews. The study was reviewed and approved by all local applicable institutional\u00a0review boards and ethics committees.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}